AL-DAWAA MEDICAL SERVICES COMPANY |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94 SAR | -0.53% |
|
-1.57% | -11.25% |
| Apr. 30 | Aldawaa Medical Services Posts Higher Q1 Net Profit, Revenue | MT |
| Apr. 30 | Al-Dawaa Medical Services Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Drug Retailers
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -11.25% | 2.14B | - | ||
| -23.66% | 11.73B | B | ||
| +12.44% | 6.3B | C | ||
| -25.24% | 6.29B | B | ||
| -9.39% | 6B | C+ | ||
| -2.04% | 4.63B | D- | ||
| +60.00% | 4.57B | C | ||
| -6.67% | 3.89B | B | ||
| -10.84% | 3.5B | C- | ||
| -6.41% | 3.04B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4163 Stock
- Ratings Al-Dawaa Medical Services Company